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Downregulation of nephrin in podocytes leads to
development of proteinuria in human and experimental
kidney diseases. However, little is understood about
pathophysiologic substances that regulate nephrin
expression. In this report, we established conditionally
immortalized reporter podocytes REPON for sensitive,
continuous monitoring of nephrin gene expression. A murine
podocyte cell line harboring a temperature-sensitive simian
virus 40 large T antigen was stably transfected with a gene
encoding secreted alkaline phosphatase (SEAP) under the
control of the 5.4 or 8.3 kb nephrin gene promoter. The
established reporter cells REPON5.4 and REPON8.3 were
exposed to various pathophysiologic substances, and culture
media were subjected to SEAP assay to identify regulators of
nephrin gene expression. Among the bioactive substances
tested, three physiological ligands of nuclear receptors
including all-trans-retinoic acid, 1,25-dihydroxyvitamin D3,
and dexamethasone significantly activated the nephrin gene
promoter in a dose-dependent manner. These effects were
observed in both REPON5.4 and REPON8.3 and were
associated with upregulation of nephrin mRNA. The effects of
these substances were synergistic, and the maximum effect
was observed by combination of three agents. In contrast,
inflammatory cytokines interleukin-1b (IL-1b) and tumor
necrosis factor-a as well as phorbol ester significantly
downregulated the activity of the nephrin promoter as well
as nephrin gene expression. These results elucidated the
bidirectional regulation of nephrin by distinct
pathophysiologic substances and may provide molecular
bases for explaining how proteinuria is induced under
pathologic situations and why some ligands for nuclear
receptors have the anti-proteinuric potential.
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Proteinuria is a typical clinical feature of renal diseases,
especially glomerular diseases. Previous reports demonstrated
that (1) increase in the level of urinary protein is toxic to the
renal tubules and causes activation of tubulointerstitial cells,
and (2) the degree of proteinuria is closely correlated with the
severity of renal diseases.1 Because of this reason, control of
proteinuria is a critical, therapeutic target in various kidney
diseases.
Under physiologic situations, structural integrity of the
glomerular filtration barrier (basement membrane and slit
diaphragm) is maintained by podocytes that regulate passage
of macromolecules in plasma into the urinary space.2 In
contrast, the integrity of the filtration barrier is often
disrupted under pathological situations, leading to develop-
ment of proteinuria. Currently, however, information
is limited regarding how the function of the filtration barrier
is regulated by endogenous bioactive substances under
pathophysiologic circumstances. In particular, endogenous
regulators for podocyte function are largely unknown.
Various mechanisms may be involved in the regulation of
glomerular filtration, but recent investigation identified
nephrin, a podocyte-specific protein, as the key regulator
involved in the structure and function of the slit diaphragm.3
Nephrin is a 185 kDa transmembrane protein with eight
immunogloblin-like domains and one fibronectin III-like
domain in the extracellular region. Normally, it exists as
complexes with other podocyte-specific proteins including
NEPH1, podocin, and CD2-associated protein.4,5 Loss of
nephrin fails to form functional complexes in the slit
diaphragm, resulting in dysfunction of the filtration barrier.
In humans, massive proteinuria and progressive renal failure
are caused by mutation of the nephrin gene in Finnish-type
congenital nephrotic syndrome.6 Similarly, disruption of the
nephrin gene in mice results in abnormal foot process
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2006 International Society of Nephrology
Received 7 November 2005; revised 6 April 2006; accepted 27 April
2006; published online 5 July 2006
Correspondence: M Kitamura, Department of Molecular Signaling, Inter-
disciplinary Graduate School of Medicine and Engineering, University of
Yamanashi, Chuo, Yamanashi 409-3898, Japan.
E-mail: masanori@yamanashi.ac.jp
892 Kidney International (2006) 70, 892–900
formation in podocytes and causes consequent nephrosis.7,8
Previous reports also showed that the level of nephrin is
attenuated in human nephrotic syndrome.9–11 Furthermore,
decreased expression of nephrin mRNA is often observed in
glomeruli from patients with a wide range of proteinuric
glomerular diseases including minimal change nephropathy,
membranous nephropathy, focal segmental glomerulosclero-
sis, immunoglobulin A nephropathy, and diabetic nephro-
pathy.9,12–14
Based on the current knowledge described above, altered
expression of nephrin is one of the major mechanisms
involved in the development of proteinuria. Currently,
however, little is known about endogenous substances that
regulate expression of nephrin in podocytes. It is mainly
because podocytes are terminally differentiated cells with
little mitogenic potential,15,16 which does not allow for
establishment of stable cell lines required for in vitro assays.
To overcome this problem, some groups have reported
establishment of conditionally immortalized podocytes from
transgenic mice harboring a gene coding for the temperature-
sensitive simian virus 40 (SV40) large T antigen under the
control of the interferon-g (IFN-g)-inducible promoter.17,18
Using the conditionally immortalized podocytes, we
aimed in the present study to establish an in vitro assay
system that allows for sensitive screening and identification
of substances that regulate the glomerular filtration barrier.
For this purpose, a secreted alkaline phosphatase (SEAP)
gene was fused to the promoter of the nephrin gene and
introduced into conditionally immortalized podocytes. Using
the established sensor cells, screening and identification of
endogenous bioactive substances involved in the regulation
of proteinuria were attempted. We especially focused on
putative anti-inflammatory substances including retinoic
acid, vitamin D3, and glucocorticoid
19–21 as well as inflam-
mation-associated cytokines and growth factors involved
in glomerular diseases.
RESULTS
Establishment of conditionally immortalized reporter
podocytes for nephrin expression (REPON)
Nephrin reporting podocytes were established by stable
transfection of conditionally immortalized murine podocytes
with pN5.4-SEAP or pN8.5-SEAP (Figure 1a). Under a non-
permissive condition (37–381C in the absence of IFN-g),
eight clones exhibited substantial levels of SEAP activity.
Typical morphologic feature of the established cells, resem-
bling that of the parental podocytes,18 is shown in Figure 1b.
In HeLa cells, all-trans-retinoic acid (ATRA) is known to
induce activation of the nephrin gene promoter.22 We
examined responses of the established clones to ATRA under
the non-permissive condition. Cells were treated with or
without 10 mM ATRA for 24 h, and the activity of SEAP in
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Figure 1 | Establishment of conditionally immortalized REPON. (a) Structure of pN5.4-SEAP and pN8.5-SEAP. The 5.4 and 8.3 kb promoter
fragments of the murine nephrin gene were subcloned into pSEAP2-Basic upstream of the SEAP gene. MCS, multicloning sites. (b) Typical
morphologic features of established REPON under subconfluent and confluent culture conditions. Phase-contrast microscopy. (c, d) Responses
of REPON to ATRA. REPON5.4(C5) precultured under a non-permissive condition were treated with (þ ) or without () 10 mM ATRA for 24 h, and
culture medium and cells were subjected to SEAP assay (c) and RT-PCR (d), respectively. Data were presented as means7s.d. An asterisk
indicates a statistically significant difference (Po0.05). In (d), molecular markers are shown on the left, and expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is shown as a loading control. RT(), reaction without reverse transcriptase.
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culture medium was evaluated. After stimulation with ATRA,
all eight clones exhibited modest increases in the level of
SEAP (1.9- to 2.9-fold). A typical result is shown in Figure 1c.
The elevation of SEAP activity was correlated with increased
expression of nephrin mRNA when examined by reverse
transcriptase-polymerase chain reaction (RT-PCR) (Figure
1d). We selected three representative clones and designated as
reporter podocytes for nephrin (REPON): REPON5.4 (clone
5 (C5) and clone 17 (C17) transfected with pN5.4-SEAP) and
REPON8.3 (clone 2 (C2) transfected with pN8.5-SEAP).
These cells were used for the following experiments.
Screening and identification of bioactive substances that
regulate expression of the nephrin gene in podocytes
For the screening and identification of exogenous and
endogenous regulators of proteinuria, REPON5.4(C5) were
seeded onto 96-well plates and cultured for 48 h under the
non-permissive condition. The cells were then treated for
24 h with various substances including ATRA (10 mM), 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3; 10
7
M), dexametha-
sone (1 mM), interleukin-1b (IL-1b) (20 ng/ml), tumor
necrosis factor-a (TNF-a; 250 U/ml), 12-o-tetradecanoyl-
phorbol-13-acetate (TPA; 50 nM), and platelet-derived
growth factor (PDGF; 20 ng/ml). After the treatment, 5 ml
of culture medium was collected from each well and
subjected to SEAP assay to evaluate the activity of the
nephrin gene promoter. As shown in Figure 2, three
physiological ligands for nuclear receptors including ATRA,
1,25(OH)2D3, and dexamethasone significantly activated the
nephrin promoter. In contrast, inflammatory cytokines IL-1b
and TNF-a as well as TPA significantly downregulated the
activity of the promoter of the nephrin gene. In this
experimental setting, PDGF had little impact.
Activation of the nephrin gene promoter by ATRA,
1,25(OH)2D3, and dexamethasone
Figure 3a shows a dose-dependent effect of ATRA in
REPON5.4(C5). Significant induction of SEAP was observed
at concentrations higher than 0.1 mM, a relatively low
concentration, and the effect was dose-dependent within
the range from 0.1 to 10 mM. ATRA 410 mM was found to be
toxic to the reporter podocytes (data not shown).
We performed time-lapse experiments to examine how
quickly REPON respond to ATRA and report activation of
the nephrin promoter. REPON5.4(C5) were treated with
10 mM ATRA, and culture media were collected periodically.
As demonstrated in Figure 3b, compared with untreated
control, significant elevation of SEAP was observed within
4 h, and the level of induction was increased for at least 48 h
in a time-dependent manner. The effect of ATRA was
observed similarly in another N5.4-based reporter clone
REPON5.4(C17) and also observed in N8.3-based clone
REPON8.3(C2) (Figure 3c).
Figures 4a and 5a show dose-dependent effects of
1,25(OH)2D3, and dexamethasone in REPON5.4(C5). Sig-
nificant induction of SEAP was observed at concentrations
higher than 109 M of 1,25(OH)2D3 and 0.1 mM of dexa-
methasone. These effects were dose-dependent, peaked at
107 M of 1,25(OH)2D3 and 1 mM of dexamethasone and
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Figure 2 | Screening and identification of bioactive substances
that regulate expression of the nephrin gene. REPON5.4(C5) cells
precultured under a non-permissive condition were treated for 24 h
with various substances including ATRA (10 mM), 1,25(OH)2D3 (10
7
M),
dexamethasone (1 mM), IL-1b (20 ng/ml), TNF-a (250 U/ml), TPA
(50 nM), and PDGF (20 ng/ml). After the treatment, 5 ml of culture
medium was collected from each well and subjected to SEAP assay to
evaluate the activity of the nephrin gene promoter. Assays were
performed in quadruplicate, and data were expressed as means7s.d.
Asterisks indicate statistically significant differences (Po0.05).
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Figure 3 | Activation of the nephrin gene promoter by ATRA.
(a) REPON5.4(C5) cells precultured under a non-permissive condition
were treated for 24 h with ATRA at different concentrations (0–10 mM),
and culture media were subjected to SEAP assay. (b) REPON5.4(C5)
cells were treated with or without 10 mM of ATRA for the indicated
time periods and subjected to SEAP assay. (c) REPON5.4(C5),
REPON5.4(C17), and REPON8.3(C2) cells were treated with 10 mM of
ATRA for 24 h and subjected to SEAP assay. Data were expressed as
means7s.d., and asterisks indicate statistically significant differences
(Po0.05). In (c), fold induction of SEAP vs unstimulated condition
is shown.
894 Kidney International (2006) 70, 892–900
o r i g i n a l a r t i c l e K Yamauchi et al.: Regulators for nephrin expression in podocytes
diminished at higher concentrations. RT-PCR confirmed that
the induction of SEAP by these substances was correlated
with upregulation of nephrin mRNA (Figures 4b and 5b).
The effects of 1,25(OH)2D3 and dexamethasone on nephrin
were also confirmed using other reporter cell lines,
REPON5.4(C17) and REPON8.5(C2) (Figures 4c and 5c).
ATRA, 1,25(OH)2D3, and dexamethasone are known to
exert their biological effects via the nuclear receptor family of
molecules that may interact with each other.23 We therefore
examined combinational effects of these agents on the
promoter activity of nephrin. REPON5.4(C5) were treated
with ATRA (10 mM), 1,25(OH)2D3 (10
7
M), and dexametha-
sone (1mM), individually or in combination, and subjected to
SEAP assay. Among three compounds tested, 1,25(OH)2D3
was the most potent for activation of the nephrin gene.
However, induction of SEAP by any combination of these
agents was significantly higher than that by any single
compound, and the maximum effect was achieved by the
combination of three agents (Figure 6). Of note, the effects of
some combination were not additive but synergistic; for
example, induction by 1,25(OH)2D3 plus dexamethasone was
2.770.1- and 1.670.1-fold respectively, whereas the induc-
tion by their combination was 7.370.5-fold.
Suppression of nephrin expression by inflammatory
cytokines
The downregulation of SEAP by IL-1b, TNF-a, and TPA,
demonstrated in Figure 2, might be caused by nonspecific
damage of the reporter podocytes. To exclude this possibility,
the identical cultures used for SEAP assay were subsequently
subjected to a formazan assay to evaluate the number of
viable cells. The result showed that none of IL-1b, TNF-a, or
TPA as well as PDGF significantly decreased cell viability
(Figure 7a). To confirm that the suppression of the nephrin
promoter was not due to nonspecific effects, conditionally
immortalized podocytes were stably transfected with the
SEAP gene under the control of the SV40 promoter. The
established cells constitutively secreting SEAP were treated
with IL-1b, TNF-a, TPA, or PDGF for 24 h, and the activity
of SEAP was evaluated. As shown in Figure 7b, none of these
agents downregulated the level of SEAP.
The suppressive effects of IL-1b, TNF-a, and TPA on
nephrin gene expression were further confirmed by RT-PCR.
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Figure 4 | Activation of the nephrin gene promoter by
1,25(OH)2D3. (a) REPON5.4(C5) cells precultured under a non-
permissive condition were treated for 24 h with 1,25(OH)2D3 at
different concentrations (0–106 M), and culture media were sub-
jected to SEAP assay. (b) REPON5.4(C5) cells were treated with (þ ) or
without () 107 M of 1,25(OH)2D3 for 24 h, and expression of nephrin
mRNA was evaluated by RT-PCR. The level of GAPDH mRNA is shown
as a loading control. RT(), reaction without reverse transcriptase.
(c) REPON5.4(C5), REPON5.4(C17), and REPON8.3(C2) cells were
treated with 107 M of 1,25(OH)2D3 for 24 h and subjected to SEAP
assay. Data were expressed as means7s.d., and asterisks indicate
statistically significant differences (Po0.05).
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Figure 5 | Activation of the nephrin gene promoter by
dexamethasone. (a) REPON5.4(C5) cells precultured under
a non-permissive condition were treated for 24 h with
1,25(OH)2D3 at different concentrations (0–100mM), and culture media
were subjected to SEAP assay. (b) REPON5.4(C5) cells were
treated with (þ ) or without () 1 mM of dexamethasone for 24 h,
and expression of nephrin mRNA was evaluated by RT-PCR.
(c) REPON5.4(C5), REPON5.4(C17), and REPON8.3(C2) cells were
treated with 1 mM of dexamethasone for 24 h and subjected to SEAP
assay. Data were expressed as means7s.d., and asterisks indicate
statistically significant differences (Po0.05).
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Consistent with the findings on the activity of the nephrin
promoter, the level of nephrin mRNA was depressed by IL-
1b, TNF-a, and TPA (Figure 7c), confirming our conclusion.
Expression of nephrin and responses to stimuli of reporter
podocytes with or without prolonged deprivation of IFN-c
In the present study, we used reporter podocytes for
experiments after depletion of IFN-g for 48 h. However, the
original work in which the conditionally immortalized
podocytes were established used longer deprivation of IFN-g
to induce full differentiation of podocytes.18 We suspected
that the duration of IFN-g deprivation could affect expres-
sion of nephrin and responses to stimuli of the established
reporter podocytes. To examine this possibility, we compared
levels of nephrin mRNA and nephrin protein as well as
activity of the nephrin gene promoter using REPON5.4(C5)
cells preincubated without IFN-g for 48 h or 9 days. As shown
in Figure 8a, the activity of the nephrin gene promoter was
not affected by the deprivation term for IFN-g. Consistently,
depletion of IFN-g for an additional 7 days only slightly
increased the level of nephrin mRNA when examined by RT-
PCR (Figure 8b). Western blot analysis also revealed that the
level of nephrin protein was unaltered by the longer depletion
of IFN-g (Figure 8c). These results clearly showed that, in our
reporter podocytes REPON, depletion of IFN-g for 48 h was
sufficient, and longer incubation was not necessary, for
substantial induction of nephrin gene and protein.
To confirm that longer deprivation of IFN-g does not
affect responses of REPON to stimuli, we compared
responses of the reporter podocytes to ATRA,
1,25(OH)2D3, dexamethasone, IL-1b, and TNF-a using the
cells preincubated without IFN-g for 48 h or 9 days. As shown
in Figure 9a, depletion of IFN-g for an additional 7 days did
not influence activation of the nephrin gene promoter by
ATRA, 1,25(OH)2D3, or dexamethasone. Furthermore, sup-
pression of the nephrin promoter by IL-1b and TNF-a was of
the same extent regardless of the duration of IFN-g
deprivation (Figure 9b). These results evidenced that
depletion of IFN-g for longer than 48 h does not affect
responses of REPON to the stimuli that regulate nephrin
expression.
DISCUSSION
Urinary protein is toxic to the tubulointerstitium in the
kidney, and persistent proteinuria facilitates progression of
renal injury and fibrosis.24 Recent investigation revealed that
nephrin is a key regulator involved in the regulation of
proteinuria.3 To date, however, little has been understood
about endogenous molecules involved in the regulation of
nephrin gene expression. In the present report, we established
reporter podocytes REPON that allow for sensitive and
continuous monitoring of nephrin gene expression. Using
this method, we screened several bioactive substances that
may be involved in glomerular pathophysiology and
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Figure 7 | Suppression of nephrin expression by inflammatory
cytokines. (a) REPON5.4(C5) cells precultured under a non-permis-
sive condition were treated for 24 h with IL-1b (20 ng/ml), TNF-a
(250 U/ml), PDGF (20 ng/ml), or TPA (50 ng/ml). After the treatment,
the cells were subjected to formazan assay to evaluate the number of
viable cells. (b) Conditionally immortalized reporter podocytes that
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were expressed as means7s.d. (c) REPON5.4(C5) cells were treated
for 24 h with IL-1b (20 ng/ml), TNF-a (250 U/ml), or TPA (50 ng/ml) and
subjected to RT-PCR. The level of GAPDH mRNA is shown as a loading
control. RT(), reaction without reverse transcriptase.
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identified that three ligands of nuclear receptors, retinoic
acid, vitamin D3, and glucocorticoid, trigger expression of
nephrin. We also revealed that proinflammatory cytokines
IL-1b and TNF-a downregulate the nephrin gene expression.
ATRA is an active metabolite of vitamin A and a ligand of
the nuclear receptor, retinoic acid receptor (RAR). After
binding of ATRA to RAR, RAR forms homodimers or
heterodimers with retinoid X receptor, and the resultant
complexes exert biological effects via binding to the
particular cis element, the retinoic acid response ele-
ments.25,26 In the present study, we found that ATRA
activated the murine nephrin promoters N8.3 and N5.4
and upregulated expression of nephrin mRNA. It is
consistent with a recent report showing that ATRA induced
differentiation of cultured podocyte with increased expres-
sion of nephrin and podocin.27 A previous report showed
that three putative retinoic acid response elements are present
in the regulatory region of the human nephrin gene.22 These
elements are functional in HeLa cells treated with ATRA
when examined by a reporter assay.22 Our current findings
indicated that the murine nephrin promoter may also
contain retinoic acid response elements or retinoic acid
response element-like sequences responsive to ATRA. Using
database analyses by Genomatix PromoterInspector (http://
www.genomatix.de)28 and TFSEARCH based on TransFac
(http://mbs.cbrc.jp/research/db/TFSEARCH.html),29 we found
single binding site for RAR at 5998 to 6016 of the
murine nephrin promoter. However, this site is present within
N8.3 but outside of N5.4, which responded similarly to ATRA
in murine podocytes (Figure 3c). This result indicated that
unidentified elements responsive to ATRA may exist in the
promoter region of the mouse nephrin gene. Of note, 25
putative RAR-RXR half-sites (50-[A/G]G[G/T][T/A]CA-30) are
present in N5.4,25 and these sites might be responsible for
induction of the nephrin gene by ATRA. Alternatively, the
effect of ATRA observed in this report may be indirect and
mediated by induction of other ATRA-responsive proteins.
Further investigation will be required to clarify the mechanism
involved.
Previous reports showed that retinoic acid was a potential
therapeutic agent for the treatment of glomerular dis-
eases.30–33 Several reports have demonstrated the anti-
proteinuric effect of retinoic acid,30,34–36 but its precise
mechanisms were largely unknown. Our current data,
together with a recent report,22 raise a possibility that
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and cells were subjected to SEAP assay and formazan assay,
respectively. The levels of SEAP were normalized by the number of
viable cells, and relative values vs untreated controls (100%) are
shown. Data were expressed as means7s.d. NS, not statistically
significant.
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retinoic acid exerts the anti-proteinuric effect via induction
or preservation of nephrin expression in podocytes.
In the present study, we elucidated that 1,25(OH)2D3
activated the nephrin promoters N8.3 and N5.4 and induced
expression of nephrin mRNA. 1,25(OH)2D3 is a biologically
active metabolite of vitamin D that acts via its nuclear
receptor, vitamin D receptor (VDR).37 After binding of
1,25(OH)2D3 to VDR, the resultant complexes exert
biological effects via the vitamin D response element.37
Using Genomatrix, we found three putative VDR binding
sites in N5.4 and five sites in N8.3. Together with the fact that
podocytes express VDR constitutively,38,39 1,25(OH)2D3
possibly induced expression of nephrin via activation of
VDR and subsequent binding to the vitamin D response
elements.
1,25(OH)2D3 is a potential therapeutic agent for the
treatment of glomerular diseases.40–44 A previous report
showed that, in subtotally nephrectomized rats, 1,25(OH)2D3
preserved the number of podocytes in glomeruli and
ameliorated albuminuria.45 However, molecular mechanisms
involved in this therapeutic effect have not been elucidated
yet. Our current finding provides a hypothesis that
1,25(OH)2D3 exerts its anti-proteinuric effect via induction
or preservation of nephrin expression in podocytes.
Like ARTA and 1,25(OH)2D3, another nuclear receptor
ligand dexamethasone also induced nephrin in podocytes.
Glucocorticoids are known to exert their biological effects via
activation of glucocorticoid receptors and subsequent bind-
ing to the glucocorticoid response element.46 Using database
analysis, we found one putative glucocorticoid response
element in the nephrin promoter at 2264 to 2282. This
result indicated that dexamethasone induced expression of
nephrin directly via binding of the activated glucocorticoid
receptors to this site. Dexamethasone and other glucocorti-
coids are well-known therapeutic drugs for the treatment of
nephrotic syndrome in immune-mediated or inflammation-
associated glomerular diseases.47 The therapeutic effects have
been ascribed to their immunosuppressive and anti-inflam-
matory actions, but in some situations, these actions do not
explain the anti-proteinuric effect. For example, activation of
the immune system and inflammation are not evident in
minimal change nephropathy that is responsive to gluco-
corticoids. Our current result indicates that, in addition to
their immunosuppressive and anti-inflammatory actions,
glucocorticoids may exert the anti-proteinuric effect by
induction of nephrin in podocytes through direct activation
of the glucocorticoid receptor–glucocorticoid response
element pathway.
In contrast to the nuclear receptor ligands, inflammatory
cytokines significantly downregulated the nephrin gene
expression. Activation of protein kinase C by TPA also
suppressed expression of nephrin. Previous reports suggested
that these inflammatory cytokines as well as activation of
protein kinase C were pathogenic and may be involved in the
development of proteinuria in glomerular diseases.1,48,49 Our
present data suggested a possibility that, under pathologic
situations, locally produced inflammatory cytokines down-
regulate expression of nephrin in podocytes, leading to
development of proteinuria. Of note, previous reports have
indicated that, in A293 human embryonic kidney cells, IL-1b,
TNF-a, and TPA upregulated nephrin expression.50,51 The
reason for the discrepancy is currently unknown, but
regulation of nephrin in podocytes might be different from
that in other cell types.
The established reporter system has several advantages for
screening and identification of substances that regulate
expression of nephrin in podocytes. First, in contrast to
unmodified podocytes, a large number of podocytes can be
prepared easily; that is, REPON can be propagated using the
permissive culture condition, and differentiation can be
induced by the non-permissive condition. Second, the
established assay system is simple and sensitive because it is
based on conventional chemiluminescent assays. Third,
small-scale assays using 96- or 384-well plates are feasible
because only 5 ml of culture medium is required for analysis.
It takes only 1 h to analyze SEAP activity. This property
allows for economical high-throughput screening of bioactive
substances in multiplicated manners using small numbers of
reporter cells. Fourth, because preparation of cell lysates is
not required, continuous assessment of nephrin gene
expression using identical cultures is possible by serial
sampling of culture medium. Fifth, SEAP is very stable in
culture medium, and its half-life is approximately 500 h.52 It
means that SEAP accumulates in medium during exposure to
stimuli and that the detection sensitivity can be improved
using longer incubation time. Because of these advantages,
the REPON-based reporter system should be a powerful tool
for screening and identification of therapeutic agents
targeting proteinuria, as shown in this report. In addition,
the established system would also be useful to identify
endogenous factors that downregulate nephrin expression
and induce proteinuria.
MATERIALS AND METHODS
Cell culture
Conditionally immortalized murine podocytes established from
H-2Kb-tsA58 transgenic mice carrying a temperature-sensitive
mutant of the SV40 large T antigen under the control of the
IFNg-inducible H-2Kb promoter were kindly provided by Dr
Karlhans Endlich (University of Heidelberg, Germany)18 and used
for studies. The podocytes were grown under a permissive
condition, that is, at 331C in RPMI-1640 medium (Invitrogen,
Carlsbad, CA, USA) containing 10% fetal bovine serum and 10 U/ml
recombinant mouse IFN-g (Peprotech, Rocky Hill, NJ, USA) in type
I collagen-coated flasks. For experiments, the cells were precultured
without IFN-g (non-permissive condition) at 371C for 48 h or 9 days
and used for studies.
Plasmid construction
The 5.4 and 8.3 kb promoter fragments of the murine nephrin gene
were excised from p5.4N-nlacF and p8.3N-nlacF plasmids (kindly
provided by Dr Lawrence B Holzman, University of Michigan
Medical School, Michigan, MI, USA)53 by digestion with KpnI and
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NcoI. After blunting the NcoI site, these fragments were subcloned
into multiple cloning sites (KpnI and blunted XhoI sites) of pSEAP2-
Basic (Clontech, Palo Alto, CA, USA), and pN5.4-SEAP and pN8.5-
SEAP were constructed (Figure 1a).
Stable transfection
Conditionally immortalized podocytes cultured under the permis-
sive condition were stably transfected with pN5.4-SEAP or pN8.5-
SEAP together with pcDNA3.1 (Invitrogen) using Lipofectamine
2000 (Invitrogen). After shifting to the non-permissive condition,
the activity of SEAP in culture medium was evaluated, and G418
(150 mg/ml)-resistant clones with substantial SEAP activity were
established. As a control clone, conditionally immortalized
podocytes were stably transfected with pSEAP2-Control (Clontech)
that introduces the SEAP gene under the control of the SV40
promoter.
Pharmacological treatment
Reporter podocytes were seeded onto 96-well culture plates at a
density of 1 104 cells/well. After incubation for 48 h or 9 days in
medium supplemented with 10% fetal bovine serum in the absence
of IFN-g, the cells were treated with reagents listed below at 371C in
the presence of 1% fetal bovine serum. After incubation for 24 h, the
activity of SEAP in culture medium was evaluated as described later.
Reagents and their concentrations used were as follows: ATRA
(0.1–10 mM; Genzyme, Cambridge, MA, USA), 1,25(OH)2D3
(1010–106 M; Chugai Pharmaceutical Co. Ltd, Tokyo, Japan),
dexamethasone (0.1–100 mM; Sigma-Aldrich Japan, Tokyo, Japan),
IL-1b (20 ng/ml; Otsuka Pharmaceutical Co. Ltd, Tokushima,
Japan), TNF-a (250 U/ml; a gift from Katsuo Noguchi, Teikyo
University School of Medicine, Tokyo, Japan), PDGF (20 ng/ml;
Perro Tech, Rocky Hill, NJ, USA), and TPA (50 nM; Sigma-Aldrich
Japan).
RT-PCR
Total RNA was extracted using TRIzol Reagent (Invitrogen), and
1 mg of RNA was subjected to reverse transcription using Omniscript
Reverse Transcriptase (Qiagen, Tokyo, Japan). Reaction mixtures
without reverse transcriptase were used as negative controls. The
following primers were purchased from Operon (Tokyo, Japan) and
used for analyses:
Nephrin:
Forward: 50-CCCCAACATCGACTTCACTT-30
Reverse: 50-GGCAGGACATCCATGTAGAG-30
GAPDH:
Forward: 50-ACCACAGTCCATGCCATCAC-30
Reverse: 50-TCCACCACCCTGTTGCTGTA-30
PCR was performed using TaKaRa Ex Taq Hot Start Version
(Takara, Kyoto, Japan) under the following conditions: 941C for
15 s, 571C for 15 s and 721C for 30 s with 25–40 cycles, and 721C for
10 min for final extension. PCR products (372 bp for nephrin and
452 bp for GAPDH) were analyzed by electrophoresis. The identity
of the PCR products was confirmed by endonuclease restriction
analysis.
Reporter assay
The activity of SEAP in culture medium was evaluated by a
chemiluminescent method using the Great EscAPe SEAP detection
kit (Clontech), as described before.54,55
Formazan assay
The number of viable cells was assessed by a formazan assay using
Cell Counting Kit-8 (Dojindo Laboratory, Kumamoto, Japan). In
brief, after collecting culture media for SEAP assay, cells in 96-well
plates were incubated at 371C for 2 h in medium containing 10%
Cell Counting Kit-8 assay solution. Absorbance (450 nm) of
formazan generated from WST-8 was measured by Spectea Max
340 (Nihon Molecular Devices, Tokyo, Japan).
Western blot analysis
Western blot analysis was performed as described before56 using
goat polyclonal anti-human nephrin antibody (N-20: sc-19000;
Santa Cruz Biotechnology, Santa Cruz, CA, USA). Nephrin protein
was visualized using the enhanced chemiluminescence system
(Amersham Biosciences, Buckinghamshire, UK). As a loading
control, the level of b-actin was evaluated using anti-b-actin
antibody (Sigma-Aldrich Japan).
Statistical analysis
Assays were performed in quadruplicate. Data were expressed as
means7s.d. Statistical analysis was performed using a non-paired
t-test to compare data in different groups. P-value o0.05 was
considered to indicate a statistically significant difference.
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